The CLIA'88 classified all clinical laboratory testing as waived, moderate, or high complexity. The eight original waived tests were characterized as simple, accurate, error-free, risk-free, and suitable for home use by nonlaboratory professionals. The subjective nature of the classification process was challenged immediately. The Clinical Laboratory Improvement Advisory Committee asked the CDC and the Health Care Financing Administration to develop objective criteria that included assessment of performance by field-test and in-house data. We examined the efficacy of the CDC protocol with empirical data from the HemoCue B-Hemoglobin Test System® submission, to assess operator competency, intra-/interoperator and between-site imprecision, and accuracy. Non-laboratory-trained operators demonstrated 2-3% imprecision (40 -200 g/L). Accuracy studies yielded a slope of 1.01, an intercept of 3.53 g/L, and r of 1.00 (52-230 g/L). Results met the protocol's Tonks' criterion for imprecision (less than one-fourth of the reference range).
US Public Law 100-578 of 1988 [1] (CLIA'88) resulted in regulations that categorized all test procedures on the basis of their complexity [2] . The legislation exempted from extensive regulation certain simple procedures, often performed by nonlaboratory professionals and (or) patients in a home healthcare setting. Because most of the regulations were waived for these procedures, the term "waived tests" became part of laboratory jargon. Through the early drafts of the CLIA regulations, the concept of waived testing underwent several iterations. The final version of CLIA'88, published in the February 28, 1992, Federal Register, placed eight general types of test devices or analytes, including some glucose and hemoglobin methodologies, into the waived category.
Before implementing CLIA'88, the CDC used a pointscoring system to classify each in vitro diagnostic test procedure or device into one of three categories. Approximately 2500 procedures were classified as high complexity, 7500 as moderate complexity, and 8 as waived. The eight tests classified initially as waived included those available over-the-counter (home use), suitable for use by non-laboratory-trained individuals, and those in which erroneous results posed no risk of serious harm to the patient. These tests essentially met the initial definition of waived, meaning free from regulation under CLIA'88. The waived category, both for the inclusions and exclusions, created immediate controversy and occupied the discussions of the Clinical Laboratory Improvement Advisory Committee almost from its initial meeting [3] . Much concern centered on these tests being used in some point-of-care situations where the exemption from regulation could be perceived as a substantial benefit. The Clinical Laboratory Improvement Advisory Committee was concerned with the subjective nature of the test classification criteria and the possibility that some tests on the list that were not error-free and that incorrect results would be truly harmful.
Pressure to place tests in the waived category also came from physicians in office settings, allied health professionals, health-conscious patients wishing to take responsibility for at least part of their healthcare, and manufacturers with vested interests in specific products. The Health Care Financing Administration (HCFA) 3 and CDC also expressed interest in expanding the waived category to retain CLIA oversight for all clinical testing as various members of Congress attempted to repeal CLIA because of its perceived burdensome requirements, particularly for physician laboratories [4] . In 1993, the CDC distributed revised draft criteria to be used by manufacturers to demonstrate a product's suitability for waived classification [5] . We and others helped assess the protocol's viability by submitting to the CDC data that demonstrated a specific product's compliance. On the basis of this input and other data, the Department of Health and Human Services published "Categorization of Waived Tests," CDC's proposed guidelines for requesting waived status, in the September 13, 1995, Federal Register [6] . This study reports our assessment of the efficacy of using the CDC protocol to elicit appropriate information to request waived status. We base the assessment on our use of the process and the actual data generated, analyzed, and submitted for approval of the device as a waived device. Table 1 summarizes key qualitative characteristics for devices to be placed in the waived category. The CDC protocol further requires manufacturers to provide operating directions for individuals with reading and comprehension skills comparable with students in the seventh grade (ages 12-14 years)-typical of most newspapers and magazines prepared for general circulation. In addition, Table 2 summarizes quantitative, field-generated data required from at least three independent test groups, in nonlaboratory settings, to demonstrate overall performance, as well as performance between and among the testing sites. Testers are to rely only on the manufacturer's written directions, not direct personal coaching.
Materials and Methods cdc protocol
The protocol's first quantitative requirement is the submission of data to demonstrate within-site, betweensite, and total imprecision in medically significant concentrations. For the field tests, HemoCue chose to use 9 sites of 11-24 testers each and had each tester analyze four concentrations of liquid control materials in duplicate. As a consequence of the Occupational Safety and Health Act's blood-borne pathogens rules [7] , no patient samples were tested, and because no actual patient samples or results were involved, Institutional Review Board approval was not required.
The protocol requires demonstration of accuracy with reference materials, patient materials, and patient materials containing interfering substances. The tests may be carried out under controlled, in-house conditions by trained laboratory personnel. The studies by HemoCue included use of surplus hospital samples drawn for routine hemoglobin analysis.
description of hemocue b-hemoglobin test system ᭨ The candidate device for this study, the HemoCue BHemoglobin Test System, is manufactured in Ä ngelholm, Sweden, and distributed by HemoCue Inc., Mission Viejo, CA. The system consists of a hand-held photometer (battery or AC line voltage) and single-use, disposable cuvettes. The unmeasured sample is introduced into the cuvette by capillary action. Once a sample (or control fluid) has been introduced into the cuvette and inserted into the instrument, the hemoglobin value is displayed 45 s later.
The intended use of the device is to provide reliable hemoglobin measurements, independent of operator skill, in sites remote from the centralized hospital laboratory. These include physician offices; screening at Women, Infants, and Childrens' Nutritional Programs; blood donor centers; hospital wards; and, on the basis of a physician's recommendation, patient self-monitoring.
The device is factory-calibrated. Its performance is verified at appropriate intervals with a reference cuvette supplied by the manufacturer. If the reference cuvette value varies by Ͼ3.0 g/L from the target value, the device is considered out-of-tolerance and unsuitable for use without cleaning and reverification. If cleaning fails to remedy the problem, the user is instructed to contact the manufacturer via a toll-free telephone number. At any time, appropriate conventional liquid controls or calibration verification materials can be analyzed. While supplemental liquid controls are not required for waived tests and not recommended for a home-care situation, they can be incorporated into routine-operation protocols in Table 1 . Qualitative requirements to demonstrate suitability for waived classification.
-Fully automated or self-contained -Uses direct, unprocessed specimens -No specimen manipulation prior to analysis and no intervention during analysis -Direct analyte concentration readout; no data calculations or conversions -Fail-safe mechanism to ensure that no results are generated when: Concentration exceeds reportable range System malfunctions Table 2 . Quantitative precision data requirements.
Be generated from field study protocols Be statistically valid and include confidence limits Evaluate performance at all medical decision points relevant to upper and lower limits of the reportable range by using at least three concentrations of the analyte being tested Evaluate between-operator imprecision by using test results of all study participants Evaluate within-site imprecision by using test results generated by a statistically valid number of study participants per site, with results obtained at a minimum of three independent sites Demonstrate that the amount of total imprecision, which includes the results of precision studies described, is less than one-fourth of the reference range for the analyte divided by the mean of the reference interval healthcare settings. Test and (or) control results, including those from the reference cuvette, are recorded manually. The Hemoglobin Test System is designed to be maintenance-free, except for replacing the batteries when needed and periodically cleaning the cuvette holder. The device performs internal, electronic self-checks. If a condition is detected that could compromise the testing process, a code is displayed, the instrument remains inoperable, and the tester is instructed to call for technical assistance.
Results

qualitative evaluation criteria
The data in support of the protocol's qualitative criteria in Table 1 are provided by the manufacturer's submission to the CDC by addressing each of the points through an explanatory narrative and by submitting the operator's manual. The HemoCue Reference Guide (operating instructions) for the B-Hemoglobin Test System was evaluated by two computerized assessment programs [8] as requiring grade 8.1 and 6.7 comprehension skills for grammar, sentence structure, and vocabulary. A group of 12 seventh graders (site 7, Table 4 ) participated in the field-test sites and performed as well as, or better than, the other eight groups. Each group received the same written instructions (also included in the CDC submission) and performed the analysis without further coaching. No trial or repeat testing was allowed.
outlier rejection
Data from any study, particularly one conducted by non-laboratory-trained personnel, would be expected to include some outliers. Although the CDC protocol does not address outliers, we rejected any data from an operator where one or more results was missing (three instances) and data reported in the wrong control group (two instances), which became obvious with inspection. The remaining data (from 158 operators) were then evaluated by hemoglobin concentration and field-test site. The mean Ϯ SD were calculated, and results exceeding 3 SD from the site mean were rejected. Out of Ͼ600 data pairs, only 2 pairs exceeded 3 SD for their site, and these also were rejected. All raw data, including the rejected data, were included in the CDC submission.
precision
To quantify performance characteristics, the CDC protocol uses measurements of imprecision, on the basis of field studies, and accuracy, on the basis of field and in-house studies. Table 2 lists requirements for quantitative data to demonstrate within-site, between-site, and total imprecision at medically significant (hemoglobin) concentrations. At each site, participants analyzed, in duplicate, liquid control materials with ϳ42, ϳ84, ϳ198, and ϳ134 g/L hemoglobin. The protocol does not specify a specific data evaluation approach but requires only that it be statistically valid. Dependent on the design of the study, this could include an analysis of variance. However, the protocol also lends itself to simplified statistical calculations, on the basis of mean Ϯ SD, as will be demonstrated.
operator imprecision
The operator imprecision assessment was based on the mean (x D ) Ϯ SD of the difference between duplicates by site. Table 3 demonstrates that performance characteristics are independent of site and operator. These data, along with those in Table 6 , are the accuracy measurements specified by the protocol to demonstrate operator competency.
within-site imprecision
The within-site imprecision was calculated by determining the mean Ϯ SD, by site, for each of the four controls (Table 4) . Each operator contributed two results for each sample. The within-site CVs ranged from 0.76% or [(1.5/ 195.9)(100)] for the high control at site 8 to 4.2% for the low-low sample at sites 1 and 4. The protocol is compatible with the F-test to determine whether any of the test 
between-site imprecision
The protocol requires evaluation of between-site imprecision. In Table 5 , the mean values from each site were used to calculate the between-site SD and CVs (n ϭ 9) for each of the four samples. The between-site CVs were 0.8 -1.3%. The 95% confidence intervals (CI) about each mean exhibit large overlap. Only 2 of the 36 site-mean values exceed the 95% CI, and none exceed the 99% CI. The t-test of the means seems to be the logical method to test for site-induced bias. Although the differences in the sitemean values in some cases (e.g., 43.1 vs 41.9) may be statistically significant, they are clinically meaningless. The protocol addresses this issue by allowing discretion as to how the data are submitted.
total imprecision
The final phase of the protocol's field-test requirements focuses on total imprecision. These data are shown in Table 6 . Not unexpectedly, the grand mean for each of the four concentrations is essentially the same as observed in Tables 4 and 5 . However, because each operator ran duplicates (in the order 1, 2, 3, 4, 1, 2, 3, 4), the absence of improved CVs with the second set of the duplicate assays suggests consistency in performance, or at least that the device is reproducible in the hands of inexperienced testers. The grand CVs were 2.86 -1.96% at 44 -198 g/L hemoglobin. The field-test data rely on imprecision measurements to demonstrate the lack of excessive tester-experiencesite-day-instrument influences. The CDC's protocol in- In the worst case, the low range, the HemoCue B-Hemoglobin Test System is 2.0 -3.0 g/L low at values near 54 g/L. Because the device actually displays results in g/dL, reads only to the nearest tenth, and truncates (i.e., does not round) the result, this could account for one-half of the error. By least-squares analysis, HemoCue vs ICSH, the slope is 1.01, the intercept 3.54 g/L, and the r (regression coefficient) value is 1.00. Table 6 , total imprecision data, collected by non-laboratory-trained operators in the field studies, also demonstrate accuracy. Because the four concentrations of control used in the studies had values assigned by the Reference Method, comparison with the mean values for each concentration demonstrates accuracy and verifies the validity of the device's calibration and stability over the study duration.
patient comparisons
The CDC protocol simply requires that the manufacturer demonstrates accuracy with patient comparisons, but it does not mandate a specific experimental protocol or particular statistical analysis. For patient comparisons, the manufacturer selected three patient groups: A, patients undergoing known prescription drug therapy; B, hospitalized patients, drug use unknown; and C, blood donors. The data are summarized in Table 8 . By inspection, comparisons of the mean Ϯ SD for the candidate and Reference Method and the regression data indicate no clinically relevant differences for these three populations. The regression data, group C especially, are very narrowly clustered between 113 and 177 g/L. In the current study, the linear least-squares calculation, as reported in the submission, indicated no apparent bias between methods. However, the protocol does not preclude the use of other methods, ranging from inspection, to Deming regression, to Bland-Altman analysis. The submitter is free to make the appropriate choice.
interference studies
The CDC protocol requests data on commonly interfering substances. Interferences were evaluated by analyzing selected samples of fresh, human whole blood by the HemoCue and ICSH methods. The studies included: carboxyhemoglobin in supplemented samples and selected patient samples with leukocytes Ͼ250 ϫ 10 9 /L, or with IgG Ͼ15 g/L, and (or) with cholesterol Ͼ8.0 mmol/L. In each case, multiple aliquots were analyzed 4 We recognize that linear regression may overestimate the intercept and that CIs for slope and intercept are accepted practice. The CDC protocol does not include this requirement, and the submission included only the information given above. Because the slope and intercept variation from the ideal case are not medically significant, the data are adequate for the intended use. 
Discussion
The CDC protocol consists of three basic parts: (a) qualitative evaluations of ancillary materials such as directions and operating procedures to illustrate the ruggedness and ease of use of the device by non-laboratory-trained persons with seventh grade reading comprehension, (b) demonstrations of performance in the field by non-laboratorytrained operators typical of potential users with quantitative evaluation criteria focused primarily on imprecision measurements, and (c) evidence of accuracy based on in-house studies, patient specimens, and skilled operators.
A major CDC qualitative evaluation criterion is: "(the device) contains fail-safe mechanisms that render no result when the test system malfunctions and initiate fail-safe mechanisms rendering no test result when the result is outside the reportable range." In the submission, the manufacturer addresses this criterion by providing directions, manuals, and an explanation of the design specifications. The HemoCue device does not have absolute lock-out capability. The device, however, displays Regression data: m ϭ 1.01, b ϭ 3.54 g/L, and r ϭ 1.00. error messages when malfunctions are detected. The tester is instructed not to use the HemoCue system until the situation is corrected. The tester is expected to run the control cuvette on a daily basis, and if the result is out of numerical tolerance, take appropriate action that is limited to cleaning the cuvette holder or calling the manufacturer. Clearly this is not absolutely fail-safe, in that operators could ignore the error messages or fail to follow the cleaning procedure. As with the rest of the CDC protocol, we conclude that the fail-safe criterion is open to interpretation.
We support the concept of engineering absolutely fail-safe systems, but feel strongly that some reliance on the tester is an accepted part of healthcare, including the home-care setting. Moreover, for home use, aggressive, substantive treatment resulting from an abnormal hemoglobin value cannot begin without a physician's involvement. When trained professionals use the device, they are expected to follow the manufacturer's directions and any additional institutional policies that may include the analysis of hemoglobin controls.
The CDC's protocol-mandated, field-test studies rely primarily on imprecision data. This strategy is insightful in that it is focused on the testing process conducted by nonlaboratory operators. However, the precision protocol seems to be modeled after those used in the 1970s to describe the performance of continuous-flow methods, specifying evaluation of within-run, between-run, between-day (including between-operator), and total imprecision. By contrast, today's testing devices are precalibrated and use disposable test cuvettes limited to one sample. The mandate to demonstrate the ruggedness and ease of use of the device through multiple sample concentrations, testers, sites, and duplicate results affords evaluators the opportunity to demonstrate the range of the device's capabilities. The protocol leaves open the choice of statistical methods ranging from inspection, mean Ϯ SD, t-tests, F-tests, and even an analysis of variance approach. The protocol's total imprecision requirement seems to suggest combining the CVs from the three types of imprecision measurements. The worst case would be expected with the lowest control. The combined imprecision obtained by adding CVs as squares and taking the square root is 4.8%, well within the suggested tolerance, i.e., one-fourth RR or Tonks' performance criterion. The imprecision-based field studies, focusing on tester, site, and internal duplicates, also address the critical qualitative areas, i.e., comprehension of directions, skill required to manipulate the device, and fundamental reproducibility from site-to-site, tester-to-tester, and over time (a calibration/accuracy issue).
The protocol's accuracy requirements allow submission of data generated in-house, under controlled conditions and by skilled operators. The field-test data (Table 6 ) also address calibration accuracy because the Reference Method values for each pool are known. Focusing first on the field-test sites, the protocol seems to lead to two conclusions. Because non-laboratory-trained operators were able to achieve the correct answers on pooled material, one may infer that the information provided in the written directions was adequate and that the intrasite means and CVs demonstrate that patients would be adequately served in terms of both accuracy and imprecision. Citing the worst possible case, a patient with a value near the lowest control (41.9 g/L hemoglobin) would be expected to fall within the range 41.9 Ϯ 2.4 g/L 95% of the time, and 41.9 Ϯ 3.6 g/L 99.7% of the time. Similar arguments on the basis of clinical relevance could be made for the other concentrations.
The in-house data document fundamental accuracy, well within clinical needs, by comparing results from a range of pooled specimens and patient samples with the Reference Method. These controlled experiments allow for statistical techniques such as regression analysis to quantify accuracy. The protocol also mandates use of a version of Tonks' formula to evaluate accuracy. Tonks originally proposed 1/4 of the normal range as a rule of thumb for assessing interlaboratory accuracy. However, the protocol's use of the 1/4 RR criterion, across all potential analytes and without consideration of clinical relevance or medical need, especially in the settings where the device is being used, seems questionable at first glance. In the case of the HemoCue B-Hemoglobin Test System, the criterion is met and appears to be clinically relevant-at least the criterion is not overly permissive or restrictive. We feel, however, that future submissions to the CDC supporting a manufacturer's request for waived status on a particular analyte should address the issue of medical need and clinical reliance in the intended-use setting. Dependent on the analyte and the situation, 1/4 RR may be inappropriately large or small.
We conclude that the CDC protocol describes a feasible approach that sets a reasonable measure for the industry when data are submitted to support a request for waived status. We are particularly cognizant that the protocol allows evaluators considerable latitude in deciding what data to present, how to interpret them, including which statistical procedures to use, and what constitutes acceptable performance. Much of the data incorporated into the FDA's 510(k) and premarket approval process can be used to develop the submission on the basis of the CDC protocol.
We were paid consultants to HemoCue. Our assignment was to take the raw data from the field studies and the in-house data submitted to the FDA under the 510(k) process and frame it in the context of the CDC protocol, thereby creating a submission that was used by the CDC to grant waived status.
